Page last updated: 2024-12-08
azotochelin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
azotochelin: siderophore from Azotobacter vinelandii; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 193592 |
| CHEMBL ID | 494132 |
| CHEBI ID | 165185 |
| SCHEMBL ID | 3441243 |
| MeSH ID | M0124036 |
Synonyms (22)
| Synonym |
|---|
| azotochelin |
| C06446 , |
| 2-n,6-n-bis(2,3-dihydroxybenzoyl)-l-lysine |
| (2s)-2,6-bis[(2,3-dihydroxybenzoyl)amino]hexanoic acid |
| n2,n6-bis(2,3-dihydroxybenzoyl)-l-lysine |
| CHEBI:165185 |
| 23369-85-9 |
| CHEMBL494132 , |
| AC1L4WM2 , |
| AC1Q5QRS , |
| n,n'-bis(2,3-dihydroxybenzoyl)-l-lysine |
| l-lysine, n2,n6-bis(2,3-dihydroxybenzoyl)- |
| n,n'-bis(2,3-dihydroxybenzoyl)lysine |
| SCHEMBL3441243 |
| surecn3441243 |
| (s)-2,6-bis(2,3-dihydroxybenzamido)hexanoic acid |
| AKOS028113056 |
| 2-n,6-n-di-(2,3-dihydroxybenzoyl)-l-lysine |
| FT-0772121 |
| 95B , |
| DTXSID50946040 |
| n~2~,n~6~-bis[(2,3-dihydroxyphenyl)(hydroxy)methylidene]lysine |
Research Excerpts
Overview
Azotochelin is a biscatecholate siderophore produced by the nitrogen-fixing soil bacterium Azotobacter vinelandii.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Azotochelin is a biscatecholate siderophore produced by the nitrogen-fixing soil bacterium Azotobacter vinelandii. " | ( Complexation of oxoanions and cationic metals by the biscatecholate siderophore azotochelin. Arnaud-Neu, F; Asfari, Z; Bellenger, JP; Kraepiel, AM; Myneni, SC; Stiefel, EI, 2007) | 2.01 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The acidification caused by the dissolution of anthropogenic carbon dioxide (CO2) in the ocean changes the chemistry and hence the bioavailability of iron (Fe), a limiting nutrient in large oceanic regions." | ( Effect of ocean acidification on iron availability to marine phytoplankton. Hopkinson, BM; Morel, FM; Shi, D; Xu, Y, 2010) | 0.36 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| N-acylglycine | An N-acyl-amino acid in which amino acid specified is glycine. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID418507 | Cytotoxicity against mouse 26-L5 cells at 7.5 uM after 24 hrs | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
| AID418504 | Antiinvasive activity against mouse 26-L5 cells assessed as inhibition of cell invasion by Matrigel assay | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
| AID418506 | Antiinvasive activity against mouse 26-L5 cells assessed as inhibition of cell invasion at 2.5 uM by Matrigel assay | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
| AID418505 | Cytotoxicity against mouse 26-L5 cells after 24 hrs | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7 | Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.11
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.11) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||